Table 3. Hepatitis A seropositive cases (%) by age-range and year, 2005–2015.
| Year | Age (years) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <1 | 1–4 | 5–9 | 10–14 | 15–19 | 20–24 | 25–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥80 | Total | |
| 2005 | 24 (66.7%) | 71 (47.7%) | 62 (65.3%) | 84 (70.6%) | 33 (66.0%) | 32 (71.1%) | 31 (59.6%) | 81 (81.0%) | 68 (85.0%) | 40 (85.1%) | 18 (94.7%) | 8 (88.9%) | 2 (66.7%) | 554 (68.9%) |
| 2006 | 27 (50.9%) | 63 (44.4%) | 65 (61.9%) | 77 (75.5%) | 53 (80.3%) | 30 (73.2%) | 33 (70.2%) | 56 (83.6%) | 60 (81.1%) | 41 (85.4%) | 20 (100%) | 9 (100%) | 2 (100%) | 536 (69.1%) |
| 2007 | 16 (45.7%) | 79 (47.3%) | 94 (62.7%) | 99 (80.5%) | 54 (80.6%) | 71 (76.3%) | 78 (83.9%) | 116 (88.6%) | 99 (90.8%) | 58 (84.1%) | 33 (100%) | 15 (93.8%) | 3 (100%) | 815 (74.8%) |
| 2008 | 42 (59.2%) | 92 (51.1%) | 113 (67.3%) | 128 (80.5%) | 102 (85.0%) | 125 (84.5%) | 150 (92.6%) | 280 (90.6%) | 220 (93.6%) | 134 (97.8%) | 82 (94.3%) | 33 (94.3%) | 11 (84.6%) | 1 512 (82.9%) |
| 2009 | 44 (56.4%) | 96 (47.3%) | 125 (74.0%) | 129 (77.7%) | 123 (88.5%) | 147 (86.5%) | 200 (85.8%) | 378 (90.0%) | 278 (94.2%) | 190 (94.1%) | 99 (95.2%) | 35 (94.6%) | 13 (100%) | 1 857 (83.3%) |
| 2010 | 81 (72.3%) | 114 (54.8%) | 144 (73.9%) | 131 (78.0%) | 179 (89.5%) | 272 (88.9%) | 424 (92.8%) | 736 (94.5%) | 470 (95.5%) | 304 (94.1%) | 135 (93.8%) | 73 (100%) | 14 (100%) | 3 077 (88.7%) |
| 2011 | 310 (85.4%) | 297 (61.9%) | 349 (80.1%) | 355 (85.5%) | 422 (92.8%) | 886 (93.7%) | 1 487 (95.7%) | 2 719 (97.3%) | 1 581 (97.2%) | 943 (97.3%) | 472 (98.1%) | 175 (99.4%) | 61 (98.4%) | 10 057 (93.5%) |
| 2012 | 65 (71.4%) | 120 (53.1%) | 156 (81.7%) | 133 (77.8%) | 180 (88.2%) | 251 (89.6%) | 395 (93.6%) | 709 (95.8%) | 441 (95.0%) | 289 (97.0%) | 172 (97.2%) | 88 (95.7%) | 26 (100%) | 3 025 (89.4%) |
| 2013 | 33 (67.4%) | 91 (45.3%) | 113 (72.0%) | 114 (82.0%) | 118 (90.1%) | 166 (86.9%) | 242 (86.1%) | 418 (87.1%) | 327 (89.1%) | 262 (94.9%) | 120 (96.0%) | 64 (97.0%) | 26 (96.3%) | 2 094 (84.1%) |
| 2014 | 43 (68.2%) | 101 (51.8%) | 140 (75.3%) | 117 (77.5%) | 107 (78.7%) | 163 (86.2%) | 230 (85.8%) | 457 (91.2%) | 336 (93.1%) | 288 (95.4%) | 170 (92.9%) | 91 (96.8%) | 33 (100%) |
2 276 (85.5%) |
| 2015 | 24 (75.0%) | 63 (63.6%) | 92 (87.6%) | 58 (80.6%) | 66 (83.5%) | 116 (87.2%) | 174 (90.6%) | 343 (93.2%) | 247 (92.9%) | 182 (94.8%) | 96 (94.1%) | 38 (97.4%) | 14 (93.3%) | 1 513 (89.3%) |
| Total |
709 (72.1%) |
1 187 (52.7%) |
1 453 (74.3%) | 1 425 (79.8%) |
1 437 (87.3%) |
2 259 (88.9%) |
3 444 (91.6%) | 6 293 (94.1%) | 4 127 (94.4%) | 2 731 (95.4%) | 1 417 (96.1%) | 629 (97.4%) | 205 (97.2%) | 27 316 (87.6%) |
| Seropositivity (%) within age-range | ≥90% | ≥75-<90% | ≥50-<75% | <50% | ||||||||||